Plain language summary of the HIMALAYA study: tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer).

Abou-Alfa GK, Lau G, Kudo M, Chan SL, Kelley RK, Furuse J, Sukeepaisarnjaroen W, Kang YK, Dao TV, De Toni EN, Rimassa L, Breder V, Vasilyev A, Heurgué A, Tam VC, Mody K, Thungappa SC, Ostapenko Y, Yau T, Azevedo S, Varela M, Cheng AL, Qin S, Galle PR, Ali S, Gupta C, Makowsky M, Kurland JF, Negro A, Sangro B

Open source

DOI: 10.2217/fon-2023-0486
Published: 2023 Dec
Container: Future oncology (London, England)
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.2217/fon-2023-0486,
  title = {Plain language summary of the HIMALAYA study: tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer).},
  author = {Abou-Alfa GK and Lau G and Kudo M and Chan SL and Kelley RK and Furuse J and Sukeepaisarnjaroen W and Kang YK and Dao TV and De Toni EN and Rimassa L and Breder V and Vasilyev A and Heurgué A and Tam VC and Mody K and Thungappa SC and Ostapenko Y and Yau T and Azevedo S and Varela M and Cheng AL and Qin S and Galle PR and Ali S and Gupta C and Makowsky M and Kurland JF and Negro A and Sangro B},
  year = {2023},
  journal = {Future oncology (London, England)},
  doi = {10.2217/fon-2023-0486},
  url = {https://doi.org/10.2217/fon-2023-0486}
}

RIS

TY  - JOUR
TI  - Plain language summary of the HIMALAYA study: tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer).
AU  - Abou-Alfa GK
AU  - Lau G
AU  - Kudo M
AU  - Chan SL
AU  - Kelley RK
AU  - Furuse J
AU  - Sukeepaisarnjaroen W
AU  - Kang YK
AU  - Dao TV
AU  - De Toni EN
AU  - Rimassa L
AU  - Breder V
AU  - Vasilyev A
AU  - Heurgué A
AU  - Tam VC
AU  - Mody K
AU  - Thungappa SC
AU  - Ostapenko Y
AU  - Yau T
AU  - Azevedo S
AU  - Varela M
AU  - Cheng AL
AU  - Qin S
AU  - Galle PR
AU  - Ali S
AU  - Gupta C
AU  - Makowsky M
AU  - Kurland JF
AU  - Negro A
AU  - Sangro B
PY  - 2023
JO  - Future oncology (London, England)
DO  - 10.2217/fon-2023-0486
UR  - https://doi.org/10.2217/fon-2023-0486
ER  -

APA

GK, A., G, L., M, K., SL, C., RK, K., J, F., W, S., YK, K., TV, D., EN, D. T., L, R., V, B., A, V., A, H., VC, T., K, M., SC, T., Y, O., T, Y., S, A., M, V., AL, C., S, Q., PR, G., S, A., C, G., M, M., JF, K., A, N., & B, S. (2023). Plain language summary of the HIMALAYA study: tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer).. Future oncology (London, England). https://doi.org/10.2217/fon-2023-0486

Source records

pubmed · retrieved 2026-09-26T21:09:45.366Z